接受自体造血干细胞移植的多发性骨髓瘤患者中与无进展生存期和总生存期改善相关的免疫特征
研究纳入2007年8月至2014年1月连续101例多发性骨髓瘤患者,在自体造血干细胞移植前后进行外周血免疫分析和骨髓微小残留病检测。移植前CD19+ B细胞计数较高与2年无进展生存期和总生存期改善相关,移植后γδ T细胞和CD4+中央记忆细胞计数较高与生存改善相关,这些关联主要在微小残留病阳性或未接受维持治疗的患者中观察到。
要点
- 移植前CD19+ B细胞最高四分位组2年无进展生存期83% vs 最低四分位组53%(P = .01)。
- 移植后γδ T细胞最高四分位组2年无进展生存期65% vs 最低四分位组45%(P = .02)。
- 移植后CD4+中央记忆细胞较高与2年总生存期改善相关(95% vs 47%,P = .0003)。
核心结论
- 概念验证研究表明,自体造血干细胞移植前后的免疫分析可对缓解深度提供互补的预后价值。
- 维持治疗似乎可以克服不良免疫特征。
- 建议在自体造血干细胞移植后新型药物维持治疗的临床试验中检测免疫分析和微小残留病,以确认其预后和管理效用。
研究设计与样本
- 研究纳入2007年8月至2014年1月连续101例多发性骨髓瘤患者。
- 患者在自体造血干细胞移植前和移植后约100天接受外周血免疫分析和骨髓微小残留病检测。
主要发现
- 移植前CD19+ B细胞计数较高与2年无进展生存期改善相关(最高四分位组83% vs 最低四分位组53%;P = .01)和总生存期改善相关(最高四分位组93% vs 最低四分位组63%;P = .0003),该效应主要在骨髓微小残留病阳性患者中观察到。
- 移植后γδ T细胞计数较高与2年无进展生存期改善相关(最高四分位组65% vs 最低四分位组45%;P = .02)和总生存期改善相关(最高四分位组89% vs 最低四分位组65%;P = .01)。
- 移植后CD4+中央记忆细胞计数较高与2年总生存期改善相关(最高四分位组95% vs 最低四分位组47%;P = .0003),但与无进展生存期无关。
- γδ T细胞和CD4+中央记忆细胞计数较高的关联主要在移植后微小残留病阴性患者和未接受维持治疗的患者中观察到。
临床怎么用
- 作者建议在自体造血干细胞移植后新型药物维持治疗的临床试验中检测免疫分析和微小残留病,以确认其预后和管理效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple therapeutic options exist for multiple myeloma (MM), including autologous hematopoietic stem cell transplantation (AHSCT). Measurement of minimal residual disease (MRD) and immune reconstitution is rapidly becoming an integral part of the care of MM patients. We investigated comprehensive immune profiling (IP) associated with progression-free survival (PFS) and overall survival (OS). From August 2007 to January 2014, 101 consecutive MM patients underwent peripheral blood IP and marrow MRD testing before and approximately 100 days after AHSCT. Higher pre-AHSCT CD19+ B-cell counts correlated with improved 2-year PFS (83% [highest quartile] vs 53% [lowest quartile]; P = .01) and OS (93% [highest quartile] vs 63% [lowest quartile]; P = .0003). This effect was seen primarily in patients with MRD-positive marrow tests. Higher γδ T-cell counts post-AHSCT correlated with improved 2-year PFS (65% [highest quartile] vs 45% [lowest quartile]; P = .02) and OS (89% [highest quartile] vs 65% [lowest quartile]; P = .01). Higher CD4+ central memory (CM) cell counts post-AHSCT were associated with improved 2-year OS (95% [upper quartile] vs 47% [lowest quartile]; P = .0003) but not PFS. The higher γδ T-cell and CD4+ CM-cell count associations were primarily observed in MRD-negative patients post-AHSCT and in patients not receiving maintenance therapy. This proof-of-concept study demonstrates that IP before and after AHSCT can be of complementary prognostic value for depth of response. Maintenance therapy seems to overcome negative IP. IP and MRD should be measured in clinical trials of maintenance therapy with novel agents post-AHSCT for MM to confirm their utility for prognosis and management.
引用
- Ho CM, McCarthy PL, Wallace PK, et al. Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv. 2017. PMID: 29296748. doi:10.1182/bloodadvances.2017005447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。